This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Astellas Pharma, Inc.

Drug Names(s): sepantronium bromide

Description: YM155 is a small molecule in injectable form that is expected to induce programmed cell death (apoptosis) in tumor tissue by suppressing survivin, an inhibitor of apoptosis.

Deal Structure: In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.

YM155 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug